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Enhancers are distal regulatory elements that
can activate tissue-specific gene expression and
are abundant throughout mammalian genomes.
Although substantial progress has been made
toward genome-wide annotation of mammalian
enhancers, their temporal activity patterns and
global contributions in the context of developmental
in vivo processes remain poorly explored. Here we
used epigenomic profiling for H3K27ac, a mark of
active enhancers, coupled to transgenic mouse
assays to examine the genome-wide utilization of
enhancers in three different mouse tissues across
seven developmental stages. The majority of the
90,000 enhancers identified exhibited tightly
temporally restricted predicted activity windows
and were associated with stage-specific biological
functions and regulatory pathways in individual tis-
sues. Comparative genomic analysis revealed that
evolutionary conservation of enhancers decreases
following midgestation across all tissues examined.
The dynamic enhancer activities uncovered in this
study illuminate rapid and pervasive temporal in vivo
changes in enhancer usage that underlie processes
central to development and disease.INTRODUCTION
Distant-acting transcriptional enhancers represent the most
abundant class of cis-regulatory sequences in mammalian
genomes (Shen et al., 2012) and are predicted to be exception-
ally tissue specific in function (Bernstein et al., 2012; Ernst et al.,
2011; Shen et al., 2012; Visel et al., 2009). They are often asso-
ciated with developmentally expressed genes (Levine, 2010)
and can drive spatially highly restricted in vivo activity patternsC(Pennacchio et al., 2006; Visel et al., 2009, 2013). Sequence-
level changes at enhancers underlie evolutionary differences be-
tween species (Jones et al., 2012) and significantly contribute to
the genetic etiology of human disease (Dickel et al., 2013; Bern-
stein et al., 2012; Ernst et al., 2011). As such, genome-widemaps
of enhancers and their activity patterns provide insight into
mechanisms of evolution, development, and disease, and signif-
icant progress has been made toward mapping these elements
in mammalian genomes (Bernstein et al., 2012; Ernst et al., 2011;
Shen et al., 2012). In parallel, in vivo transcriptome profiling of
developing tissues has revealed highly dynamic gene expression
during tissue ontogenesis (Bruneau, 2008; Kang et al., 2011; Si-
Tayeb et al., 2010), and dysregulation of transient developmental
gene-expression patterns has been linked to congenital defects
and pathogenic traits (Garg et al., 2005; Hoerder-Suabedissen
et al., 2013). Differences in the chromatin landscape between
individual adult and embryonic tissues and in cultured cells (Gif-
ford et al., 2013; Heintzman et al., 2009; Shen et al., 2012; Ster-
gachis et al., 2013; Zhu et al., 2013; Ziller et al., 2013) raise the
possibility that, within a given tissue, the genome-wide regula-
tory architecture might change substantially across develop-
mental stages. Although these initial lines of evidence suggest
that enhancers may play a significant role in the extensive
changes in gene expression observed throughout mammalian
development, the in vivo dynamics of enhancer utilization as
individual tissues develop pre- and postnatally have been mini-
mally explored. Profiling enhancer activity in developing tissues
across a controlled time course has the potential to reveal the
temporal dynamics of mammalian enhancer usage in vivo and
capture regulatory landscapes orchestrating transient biological
processes that are central to human health and disease.
RESULTS
Mapping Enhancer Activity Landscapes via H3K27ac
Profiling of Mouse Tissues
To examine genome-wide enhancer activity at a consistent and
defined temporal resolution, we performed epigenomicmapping
of active enhancers across a developmental time series in threeell 155, 1521–1531, December 19, 2013 ª2013 Elsevier Inc. 1521
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Figure 1. Mapping In Vivo Enhancers via ChIP-Seq Performed on Mouse Forebrain, Heart, and Liver Tissue
(A) Schematic of developmental stages and tissues.
(B) Representative examples of putative enhancers exhibiting dynamic H3K27ac signal across tissues and time points. Text includes description of loci.
See also Figures S1 and S2 and Table S1.organs with different anatomical and physiological trajectories:
forebrain, heart, and liver. The forebrain is the center of many
higher brain functions, arising from the ectoderm and undergo-
ing waves of neurogenesis and migration during mid-embryo-
genesis, with substantial late maturation (Austin and Cepko,
1990; Clinton et al., 2000; Kang et al., 2011). The heart arises
from the mesoderm, is one of the earliest organs to form with
basic patterning complete by late gestation, and performs the
singular function of circulation throughout life (Brand, 2003; Har-
vey, 2002; Olson, 2006). The liver arises from the endoderm and
goes through a major functional transition, switching from fetal
hematopoiesis to its mature functions of detoxification, meta-
bolism, and plasma protein and hormone synthesis late in gesta-
tion (Zhao and Duncan, 2005; Zorn, 2008). These three tissues
are of significant relevance to biomedical research, and patho-
genic traits associated with all three systems are closely linked
to transient developmental processes.
We generated genome-widemaps of enhancers active in each
of these organs via chromatin immunoprecipitation sequencing
(ChIP-seq) performed directly on mouse tissue collected at
different stages of development (Figure 1A). The developmental
stages (embryonic days [E] 11.5, 14.5, and 17.5; postnatal days
[P] 0, 7, 21, and 56) and tissues were selected to capture signif-
icant developmental processes in these major organ systems. In
total, we profiled 21 unique tissue types collected from pre- and
postnatal mice (Table S1 available online). We assessed the
tissue- and stage-specific presence of H3K27ac, a histone
modification found at active enhancers (Creyghton et al., 2010;
Rada-Iglesias et al., 2011) and at transcription start sites1522 Cell 155, 1521–1531, December 19, 2013 ª2013 Elsevier Inc.(TSSs). Figure S1 shows a schematic overview of the analysis.
ChIP-seq reads were mapped to mm9, and peaks were called
for each data set (see Extended Experimental Procedures for
details for all analyses). We separated the H3K27ac-enriched re-
gions into putative distal enhancers, defined as regions posi-
tioned at least 1 kb from a known TSS, and proximal regions
that were within 1 kb of or overlapped a TSS. In total, across
the three tissues and seven time points examined, we identified
105,394 H3K27ac-enriched regions, including 16,225 regions
that were proximal to known TSSs and 89,169 distal regions rep-
resenting putative developmental enhancers. Comparison of
expression levels of the nearest TSS for both forebrain and
heart enhancers showed significantly increased expression in
the linked tissue at E11.5 (t test p values: forebrain = 0.007;
heart = 0.03). H3K27ac enrichment profiles for biological repli-
cates for a subset of samples showed significant reproducibility
across data sets (Figure S2A). The association of enhancers with
gene expression, the biological reproducibility of ChIP-seq ex-
periments, and patterns of H3K27ac coenrichment across tis-
sues and time points support the validity of these data sets for
genome-wide enhancer analysis (Figure S2).
Recent studies of chromatin indicate that H3K27ac is present
at enhancers when they are active (Bonn et al., 2012; Cotney
et al., 2012; Creyghton et al., 2010; Rada-Iglesias et al., 2011),
suggesting a model wherein dynamic H3K27ac enrichment is
associated with transient enhancer activity. This notion is illus-
trated by examples of differential H3K27ac enrichment across
time points and tissues at representative putative distal en-
hancers located near selected developmentally active target
genes (Figure 1B). For instance, an enhancer with early forebrain
H3K27ac enrichment was identified near Sox11, a gene critical
for prenatal forebrain patterning (Bergsland et al., 2011; Shim
et al., 2012; Uwanogho et al., 1995). In contrast, a region with
postnatal H3K27ac enrichment in the forebrain was identified
near Gnaz, a gene associated with dopamine signaling in the
postnatal/adult forebrain (Hendry et al., 2000; Hinton et al.,
1990; Leck et al., 2006; Sidhu et al., 1998). In the heart, two
enhancers with early and late enrichment peaks were identified
near Igf1r andAdcy5, consistent with known roles of these genes
in early heart development and later cardiomyocyte survival,
respectively (Donath et al., 1994; Holzenberger et al., 2000; Hu
et al., 2009; Iwatsubo et al., 2004; Laustsen et al., 2007). Exam-
ples in the liver include a prenatal enhancer near Hbb-b1, which
encodes a hemoglobin protein expressed in the embryonic liver
during fetal hematopoiesis (Whitney, 1977), and Lipc, which
encodes a hepatic lipase active in the mature liver that is impli-
cated in cardiovascular disease in humans (Zambon et al.,
2003). These examples suggest that dynamic chromatin modifi-
cation is detectable at enhancers examined across develop-
mental stages.
To investigate dynamic chromatin modification patterns
genome-wide, the complete set of peaks called across all data
sets was merged by combining peaks where the highest points
of enrichment within individual peaks were within 1 kb. Each
merged peak was then scored for enhancer activity across the
21 data sets based on H3K27ac signal strength. The results
from this analysis show that time points next to each other and
from the same tissue have the most similar H3K27ac enrichment
profiles, as expected based on spatial and temporal relation-
ships of the profiled tissues (Figure S2B). Initial clustering anal-
ysis indicated that developmental enhancers identified in this
study largely exhibited restricted H3K27ac enrichment across
tissues and temporally across developmental time points (Fig-
ure S2C). Using an enrichment classification method robust to
false negatives in the ChIP-seq data, we predicted the activity
windows of all enhancers identified in the three tissues. In com-
parison to shuffled data, predicted activity showed significant
temporal and spatial correlation structure across time points
and tissues, indicating that the patterns we observe represent
real biological patterns.
Although differences in the genome-wide enhancer landscape
between developing and mature tissues are known to exist in
principle (May et al., 2012; Shen et al., 2012), this time-course
profiling of an enhancer-specific chromatin mark enables longi-
tudinal examination of predicted in vivo enhancer activities at
high temporal resolution. In most cases (forebrain 85%; heart
66%; liver 80%), the predicted tissue-specific temporal activity
window of putative enhancers spanned only a subset of the
developmental stages examined (Figure 2A). The three tissues
exhibit different patterns with regard to predicted enhancer
activity across stages that are in line with their respective devel-
opmental trajectories (Figures 2A–2D and S2). For example, a
larger proportion of putative heart enhancers exhibit constitutive
predicted activity, consistent with the embryonic heart already
attaining many aspects of its mature function at E11.5, the
earliest time point profiled. Putative distal enhancers map to
both intergenic (42%) and intragenic (58%) chromosomal re-Cgions, where they overlap with intronic sequence (41%), coding
exons (9%), and untranslated regions (8%) (Figure 2B). In addi-
tion to temporal activity restrictions, candidate enhancers were
predicted to be predominantly tissue specific (Figure 2C), with
42,976 (48%) expected to be active only in one of the three tis-
sues examined. Illustrating the rapidly changing enhancer land-
scape, 40,696 (45%) of putative distal enhancers identified here
are predicted to have highly restricted temporal activity, with
enrichment spanning at most two consecutive time points in a
given tissue (Figure 2D). Although many enhancers that exhibit
short activity windows are tissue specific, we also identified clus-
ters of enhancers with predicted activity across multiple tissues
(Figure S2) that may control general or shared developmental
and/or functional processes. Considering only the3% of puta-
tive enhancers that showed constitutive H3K27ac enrichment
across all tissues and time points, we observe strong enrichment
near genes associated with hematological traits, suggesting that
such enhancers are active in blood lineages present in all tissue
samples. In contrast to the dynamic epigenomic landscape of
enhancers, H3K27ac enrichment at TSSs does not exhibit
such tissue- or stage-specific patterns, with 74% of TSSs exhib-
iting enrichment across all three tissues and the majority of TSS-
proximal sites exhibiting constitutive enrichment within a tissue
across all time points (forebrain 75%; heart 79%; liver 73%)
(Figures 2B and S2). Overall, these results suggest that the
genome-wide enhancer landscape active in each of the three
organs undergoes extensive and fast-paced turnover during
development.
In Vivo Validation of Enhancer Activity Predictions
The genome-wide changes in H3K27ac enrichment across
stages support the prevalence of dynamic enhancer activity
based on a known epigenomic signature of active enhancers.
To obtain direct evidence of developmentally dynamic enhancer
activities, we used an established transgenic mouse enhancer
reporter assay (Kothary et al., 1989; Pennacchio et al., 2006) to
experimentally validate enhancer activity predictions (Figure 3).
Whole-mount staining of the transgenic mice generated in this
assay is possible at E11.5 and E14.5, enabling interrogation of
higher numbers of candidate enhancers at these early develop-
mental stages compared to later time points, when sectioning is
required. As such, we used three strategies to validate H3K27ac-
based activity predictions using these assays. First, to establish
baseline success rates for in vivo activity predictions made from
H3K27ac data sets, we examined sequences predicted to be
active forebrain enhancers at E11.5, where 12/18 (67%) drove
reproducible expression patterns in vivo (Figures 3A and S3).
This rate of validated in vivo activity is similar to that of other epi-
genomic marks of active enhancers, such as p300 (Visel et al.,
2009), and is significantly higher than the rate of in vivo forebrain
enhancer activity among a control set of tested highly conserved
noncoding presumed functional elements (Pennacchio et al.,
2006) (Fisher’s exact test, p = 6 3 106). Next, we examined
in vivo activity of a smaller set of eight enhancers at multiple
time points to validate that change in H3K27ac enrichment
corresponded to changes in in vivo activity. We examined se-
quences that were known to be inactive in vivo at E11.5 (Pennac-
chio et al., 2006) but exhibited an H3K27ac enrichment profileell 155, 1521–1531, December 19, 2013 ª2013 Elsevier Inc. 1523
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Figure 2. Developmental Enhancers Exhibit Dynamic H3K27ac Enrichment Associated with In Vivo Activity
(A) Heatmap displaying H3K27ac enrichment by tissue and time point for putative distal enhancers (forebrain, n = 52,175; heart, n = 55,869; liver, n = 46,062). For
each tissue, each row of the heatmap shows relative H3K27ac enrichment at one enhancer, with signal across the surrounding 10 kb region plotted. Enhancers
are organized by the number of time points at which the enhancer is active, starting with constitutively active enhancers at the top and proceeding down to single-
stage enhancers at the bottom.
(B) Breakdown on H3K27ac enrichment across genomic features.
(C) Tissue specificity for TSS and distal H3K27ac enrichment.
(D) Predicted length of putative distal enhancer activity based on H3K27ac enrichment across seven profiled time points.
See also Figure S2.that suggested activity at later time points. 5/8 (63%) of the ele-
ments tested showed reproducible in vivo forebrain activity at a
later time point consistent with the developmental H3K27ac
signature (Figure S4). We additionally re-examined two elements
where activity was predicted to subside later in development and
that were active in E11.5. In one of the two, we observed no
reproducible LacZ staining at E17.5 or P0. Representative stain-
ing patterns for two dynamic enhancers are shown in Figures 3B
and 3C. First, an enhancer near Scn2a1, a sodium channel gene
expressed in the forebrain between E11.5 and E14.5 (Albrieux
et al., 2004) that is required for normal brain development
(Planells-Cases et al., 2000) and mutated in autism (Sanders
et al., 2012), showed highly reproducible cortical expression at
E11.5 but not at P0 (Figure 3B). Second, an enhancer near Elavl2,1524 Cell 155, 1521–1531, December 19, 2013 ª2013 Elsevier Inc.a gene important to neuronal differentiation (Akamatsu et al.,
1999), had no activity at E11.5 but drove reproducible expres-
sion in the hippocampus at P0 (Figure 3C). Finally, we tested
six enhancers where the human orthologous region overlapped
a lead genome-wide association study (GWAS) single-nucleo-
tide polymorphism (SNP) associated with a forebrain, heart, or
liver phenotype. The lead SNPs overlapped by the tested en-
hancers were not in linkage disequilibrium with a coding SNP,
and lead SNPs overlapped with putative transcription factor
(TF)-binding motifs predicted using HaploReg (Ward and Kellis,
2012). All six candidate enhancers drove expression in the
predicted tissue at E14.5 (Figure S5). Three representative en-
hancers that overlap GWAS lead SNPs are shown in Figure 3D,
including an enhancer active in the fetal mouse liver that contains
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Figure 3. In Vivo Validation of H3K27ac-Predicted Enhancer Activity
Candidate enhancers were cloned into a vector containing a minimal promoter and the LacZ reporter gene and injected into fertilized mouse oocytes. Multiple
transgenic mice with independent enhancer integration events were examined to assess the reproducibility of any given reporter activity pattern. Yellow arrows
and numbers next to embryos/sections indicate reproducibility of staining across transgenic individuals. Additional embryo images for each element can be
viewed in the VISTA Enhancer Database (http://enhancer.lbl.gov). n.r., not reproducible.
(A–C) In vivo validation of predicted forebrain enhancers. Forebrain H3K27ac signal across time points shown to the left, with yellow highlighting indicating the
tested region. (A) Six representative enhancers that exhibit diverse forebrain activity patterns at E11.5. (B) Enhancer located near Scn2a1 that shows transient
H3K27ac enrichment and drives in vivo expression at E11.5, but not P0. (C) Enhancer upstream of Elavl2 that shows transient enrichment and in vivo activity at P0,
but not E11.5. Blue arrows indicate nonreproducible staining.
(D) Three representative enhancers active at E14.5 that overlap with lead GWAS SNPs. For mm1119, reproducible staining was also present in liver, consistent
with H3K27ac enrichment in E14.5 liver (not shown). GWAS phenotype, lead SNP ID, and potential gene of interest are listed.
See also Figures S3, S4, and S5.a SNP associated with levels of blood cells with fetal hemoglobin
(F-cells) in adults (Bhatnagar et al., 2011; Menzel et al., 2007), an
enhancer that is active in the developing mouse forebrain that
contains a lead SNP for depression and alcohol dependence
(Edwards et al., 2012), and a mouse heart and liver enhancer
that contains a SNP associated with adiponectin levels (Dastani
et al., 2012). These experimentally validated enhancer activity
patterns provide in vivo evidence suggesting plausible patho-
genic mechanisms of noncoding variation via spatiotemporally
restricted impact on target gene expression caused by changes
in enhancer sequence. In total, 23/32 (72%) putative enhancers
tested in transgenic mice drove H3K27ac-predicted expression
patterns in vivo, and many of these enhancers were associated
with critical developmental genes or potentially pathogenic
variation. Full transgenic results from all experiments performed
for this study are available on the VISTA website (http://
enhancer.lbl.gov/). Together, the genome-wide ChIP-seq data
and the complementary transgenic validation of a subset of dy-Cnamic activity predictions support the existence of very large
numbers of enhancers with restricted activity intervals across
development.
Enhancers Control Dynamic Developmental Processes
and Are Enriched for TF-Binding Motifs and Disease-
Associated Variation
To assess correlation between the predicted temporal activity
of enhancers and biological function beyond anecdotal exam-
ples, we examined on a genome-wide scale whether putative
enhancers can be linked to biological processes, mouse pheno-
types, and regulatory pathways associated with the develop-
mental stages profiled (Heinz et al., 2010; McLean et al., 2010).
Putative enhancers are globally enriched near genes that have
pertinent tissue- and time point-related functional annotations
and are enriched for relevant TF-binding sites. For example,
enhancers predicted to be active early in forebrain development
are enriched for annotation terms such as neural precursor cellell 155, 1521–1531, December 19, 2013 ª2013 Elsevier Inc. 1525
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Figure 4. Association of Developmental
Enhancers with Functional Pathways,
Mouse Phenotypes, and TF-Binding Motifs
Each heatmap displays results from enrichment
analysis performed on forebrain, heart, and liver
enhancers active at specified time points.
(A) Ten representative differentially enriched GO
biological functions, MGI mouse phenotypes, and
known TF-binding motifs selected from the com-
plete enrichment data sets.
(B) Full enrichment data set heatmaps for GO
biological functions (n = 827), MGI mouse pheno-
types (n = 922), and known TF-binding motifs
(n = 215). Annotation terms and TF motifs were
hierarchically clustered by enrichment patterns.
Differential enrichment across tissues and time
points occurs widely across the full data sets.proliferation and axonogenesis and binding motifs of TFs that
control neuronal differentiation, such as Lhx3. In contrast, en-
hancers predicted to be active later in forebrain development
are enriched for biological processes such as synaptic transmis-
sion and cognition and phenotypes including abnormal learning/
memory/conditioning and neurodegeneration. Figure 4A shows
ten representative functions, phenotypes, and binding motifs
that exhibit strong differential enrichment patterns across tis-
sues and developmental stages, with such differential patterns
recapitulated across the entire set of enriched annotation terms
and bindingmotifs, as shown in Figure 4B. Finally, intersection of
putative enhancers identified here with results from genome-
wide association studies (Hindorff et al., 2009) showed that
disease-associated SNPs are more likely to be located nearby1526 Cell 155, 1521–1531, December 19, 2013 ª2013 Elsevier Inc.candidate enhancers compared to
randomly sampled SNPs (see Extended
Experimental Procedures). These results
demonstrate that transiently active
developmental enhancers are centrally
involved in the control of biological
processes required for tissue ontogen-
esis and function, regulating genes
essential to developmental and disease
phenotypes.
Evolutionary Pressure on
Enhancers Changes across
Development
Despite the general utility of evolutionary
conservation as a mark of regulatory se-
quences (Pennacchio and Rubin, 2001),
studies in mammalian cell lines and tis-
sues have produced contradictory find-
ings regarding the global conservation
levels of enhancers (Blow et al., 2010;
Bernstein et al., 2012; Pennacchio et al.,
2006; Shen et al., 2012). The maps of pre-
dicted enhancer activity in the present
study, obtained with consistent method-
ology across tissues and developmentalstages, provide an opportunity to examine the evolutionary con-
servation of enhancers using rigorous comparative genomic
measurements. To test whether evolutionary pressure on en-
hancers varies across tissues or developmental stages, the
most constrained core regions of noncoding putative distal
enhancers active at different developmental stages were
compared using two related measures of sequence evolution,
conservation (evolutionary age based on divergence between
mouse and most distant vertebrate lineage exhibiting sequence
homology to mouse) and constraint (estimate of local sequence
conservation across vertebrates). In addition to tissue-derived
data, we incorporated in this analysis H3K27ac ChIP-seq
data from mouse embryonic stem cells (ESCs) and three cell
lineages, neural progenitors, mesoderm, and mesoendoderm,
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Figure 5. Developmental Signatures of Enhancer Evolution
The tissue-based enhancer set was expanded to include cell lines used as proxies for early development: embryonic stem cells (ESC), neural progenitors (NP),
mesoderm (MES), and mesoendoderm (END).
(A) Mean and 95% and 80% confidence intervals of evolutionary age (left panel) and constraint (right panel) by tissue and time point.
(B) Cumulative proportion of enhancers conserved across the vertebrate tree (shown on right) as defined by enhancer sequence homology. Plots shown for all
time points in each individual tissue in the first three panels, with higher mean conservation indicated by darker shades. Far-right panel shows differences across
tissues at the most constrained stage for each tissue.
See also Figures S6 and S7.as experimentally accessible proxies for major lineages of the
forebrain, heart, and liver at stages prior to E11.5.
Strikingly, we observed substantial differences in evolutionary
conservation and sequence constraint of putative enhancers
compared both within a given tissue across time points and
across tissues at the same time point (Figure 5A). Predicted fore-
brain enhancers exhibit higher overall constraint and are more
conserved across the vertebrate tree than enhancers predicted
to be active in heart or liver, verifying previous findings
comparing enhancers active at E11.5 identified by p300 binding
(Blow et al., 2010). However, for all tissues, the maximum levels
of evolutionary conservation/constraint of putative enhancers
were observed in early embryogenesis, with a second phase of
temporarily increased conservation/constraint in the liver in early
postnatal development. These differences result in distinct tis-
sue-specific evolutionary signatures of in vivo enhancers across
development that were robustly reproduced using alternativeCconstraint metrics, phylogenetic comparisons, and expected
enhancer core sizes (Figure S6).
To examine the evolutionary history of enhancers, the cumula-
tive percent of enhancers conserved across each transition was
determined using sequence homology across the 100 most
constrained bases, plotted in Figure 4B. The color of plotted
lines correlates with the summary measures for the data set
(shown in Figure 4A), with darker color tones indicating stronger
overall constraint/conservation. We reasoned that if specific
evolutionary transitions disproportionally contributed to the
overall differences in conservation observed across tissues
and time points, the effect would be reflected by large differ-
ences between stages/tissues at specific transitions across the
vertebrate tree. For example, the transition to a fully septated
heart, present through chicken but not in frogs or more distant
vertebrates (Olson, 2006), might be associated with a sig-
nificantly lower proportion of enhancers conserved across theell 155, 1521–1531, December 19, 2013 ª2013 Elsevier Inc. 1527
transition from tetrapods to amniotes relative to the transition
from amniotes to placental mammals. Across accessible evolu-
tionary divergence events, the relative proportions of conserved
enhancers recapitulated the general patterns observed for
mean conservation and constraint (Figure 5B). At least at the
level of whole-organ development, these results suggest that
the observed tissue- and stage-specific differences represent
cumulative effects of increased selective pressure on enhancers
active early in embryonic development throughout more than
400 million years of vertebrate evolution.
We observed two further relationships with enhancer
constraint: positive correlation between constraint and distance
from the nearest TSS and a TSS distance-independent effect
where intergenic enhancers exhibited increased constraint
versus intronic enhancers (Figure S7). These patterns are mani-
fested by a larger proportion of enhancers with predicted activity
in mature tissues located nearby the TSS and within gene bodies
relative to the same tissues at earlier stages, a pattern that is
partially consistent with recent findings comparing adult tissues
to differentiating cell lineages (Zhu et al., 2013). The strength of
these patterns varied across tissues, with forebrain exhibiting in-
creases in the difference in distance to the nearest TSS and pro-
portion of intronic enhancers between time points relative to the
other two tissues. These patterns indicate that constraint and
position in the genome are interconnected with regard to stage
of enhancer activity and suggest that these patterns may be
driven by general aspects of genome evolution and structure.
DISCUSSION
We report the developmental activity annotation of nearly 90,000
candidate distal enhancers across three major mammalian
organ systems. These genome-wide enhancer activity profiles
obtained directly from ex vivo tissues across multiple stages of
the mammalian lifespan provide insight into the temporal utiliza-
tion of enhancers as it occurs in vivo in the developing organism.
Mapping dynamic H3K27ac enrichment alone is a basic model
for enhancer identification and activity prediction, as H3K27ac
is unlikely to be present at all active enhancers, may not correlate
universally with enhancer activity, and may be present at other
noncoding genomic features. In the future, concurrent analysis
of additional informative chromatin marks and genome-wide
binding or transcription data sets is likely to refine enhancer
activity maps further, enabling increased sensitivity and speci-
ficity with regard to enhancer activity predictions and a corre-
sponding increase in the success rate of in vivo validation
assays. These limitations notwithstanding, the strong global sig-
natures of dynamic predicted enhancer activity in our results
coupled with transgenic validation of in vivo activity predictions
demonstrate the power of interrogating relevant tissues across
developmental transitions. Most of the candidate enhancers
identified here are predicted to have tightly restricted temporal
activity windows, indicating that dynamic processes in mamma-
lian development and tissue ontogenesis are regulated by
the transient activities of large numbers of temporally and
spatially restricted developmental enhancers. The rapid tempo-
ral changes in enhancer landscape identified via time-course
profiling mirror patterns of dynamic gene expression across1528 Cell 155, 1521–1531, December 19, 2013 ª2013 Elsevier Inc.development, suggesting that regulatory control of spatiotem-
poral gene-expression patterns is accomplished through the
combinatorial activity of regulatory elements that far outnumber
coding genes. These findings have major ramifications in the
context of predicting regulatory elements controlling clinically
relevant tissue- and stage-specific processes and regarding
efforts to systematically map enhancers in the human genome.
While validating the importance and impact of large-scale efforts
to annotate functional genomic elements, our observations
also highlight a substantial challenge in producing a complete
functional annotation of all distant-acting enhancers in thehuman
genome. The large numbers of putative enhancers identified here
with predicted short activity windows in specific tissues suggest
that tightly spaced developmental time series from diverse
panels of tissues may be required to capture a truly comprehen-
sive picture of the genome-wide enhancer landscape.
The observation of very high constraint of enhancers predicted
to be active at mid-gestation corroborates and partially explains
reports that as many as half of all extremely conserved noncod-
ing sequences may act as enhancers in vivo at E11.5, with
particular enrichment for neuronal tissue activities (Pennacchio
et al., 2006; Visel et al., 2008). These findings are in line with
recent whole-embryo transcriptome studies of zebrafish and
Drosophila and with evolutionary signatures observed at regula-
tory sequences across human cell lineages that support the
evolutionary hourglass model of development (Domazet-Loso
and Tautz, 2010; Kalinka et al., 2010; Stergachis et al., 2013).
This model posits that increased evolutionary constraint at crit-
ical stages of embryogenesis produces high levels of similarity
across evolutionary lineages during early development, with
relaxed constraint and increased evolutionary divergence before
and after these critical stages (Raff, 1996). The results from this
study show that distinct patterns of sequence evolution apply
to enhancers with transient in vivo activities in mammalian devel-
opment and identify tissue-specific variation in the timing and
level of maximum constraint that suggest differences in the
evolutionary history of different organ systems. The tissue-spe-
cific differences in the timing of maximal enhancer constraint
coincide with transitional phases during the ontogenesis of these
three organs. Enhancer constraint in the developing forebrain
peaks at E11.5 and continues to be high at E14.5, spanning crit-
ical stages of forebrain patterning and neuronal migration (Austin
and Cepko, 1990). In contrast, maximal constraint in the heart is
observed at E11.5, consistent with early maturation of the heart
during embryogenesis (Harvey, 2002), and average enhancer
constraint is relatively stable from E17.5 through P56. In liver, a
similar early maximum in enhancer constraint is present, with a
secondary peak around P7, which tracks the transition from fetal
hematopoiesis to the assumption of the predominantly meta-
bolic functions of the mature liver (Zorn, 2008). Although these
explanations are speculative, it is clear that evolutionary pres-
sure on enhancers changes in a tissue-specific manner across
development. These dynamic evolutionary signatures of active
enhancers reconcile previous contradicting findings regarding
constraint of mammalian enhancers, illuminate evolutionary
forces shaping development, and reinforce the long-held notion
that regulatory DNA is a primary substrate upon which evolution
acts (King and Wilson, 1975).
EXPERIMENTAL PROCEDURES
The Extended Experimental Procedures contain detailed methods and refer-
ences for all analyses described in the text and below. All custom analysis
scripts are available from the authors at request.
ChIP-Seq
Tissues from pre- and postnatal CD-1 mice were collected on ice, crosslinked
using formaldehyde, and lysed with SDS-based reagents, and chromatin was
sonicated on a Diagenode Bioruptor instrument using ChIP-seq protocols
optimized for mouse tissues (Visel et al., 2009). Chromatin immunoprecepita-
tion (ChIP) was performed using antibodies for H3K27ac (Abcam Ab4729).
Prepared libraries from ChIP and input DNA were sequenced on an Illumina
HiSeq instrument. For all experiments, reads were mapped to mm9 using
BWA (Li and Durbin, 2009), and peaks were called using MACS (Zhang
et al., 2008).
Enhancer Activity Prediction and In Vivo Validation
Using the merged set of H3K27ac peaks, enrichment for each region in
each data set was scored based on comparison of coverage within the
candidate enhancer versus experiment background after input correction.
Enrichment scores across experiments were analyzed using both unsuper-
vised and supervised approaches to determine the tissue- and stage-spe-
cific activity profiles for each putative enhancer. Activity predictions were
validated using an established mouse transgenic system (Kothary et al.,
1989; Pennacchio et al., 2006), where a vector containing a candidate
enhancer, a minimal promoter, and the LacZ gene are stably integrated
into the mouse genome via standard pronuclear injection. An enhancer
was considered validated if the LacZ staining pattern driven by the enhancer
in F0 transgenic mice was consistent with the H3K27ac predicted activity
across independent transgenic mice representing independent insertion
events in the mouse genome.
Functional and Evolutionary Analysis
Functional annotation of putative enhancers was performed with the GREAT
tool (McLean et al., 2010), which tests for global enhancer enrichment near
annotated gene classes. Motif analysis was performed with the HOMER tool
(Heinz et al., 2010). Overlap with GWAS SNPs (Hindorff et al., 2009) was
compared to overlap with non-GWAS SNPs present on standard genotyping
arrays, and individual candidate enhancers harboring GWAS SNPs were
selected for validation of enhancer activity via the transgenic assay. Evolu-
tionary analysis included six additional cell-derived H3K27ac ChIP-seq data
sets that were processed using the same methods. Base-wise sequence
homology and evolutionary constraint were compared for the core enhancer
region (defined as the 100 bp within the enhancer regions exhibiting maximal
constraint) across accessible vertebrate genomes. Additional details are re-
ported in the Extended Experimental Procedures.
Access to Full Data Sets
Complete data files are available online at http://enhancer.lbl.gov/mouse_
timecourse and include enhancer predictions mapped to the mouse reference
genome (mm9) in BED and TXT format, predicted enhancer coordinates lifted
over to the human reference genome (hg19), overlap between predicted
enhancers and lead GWAS SNPs, and results from functional annotation
and motif enrichment analyses as text files and labeled heatmaps.
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nlm.nih.gov/geo/) under accession number GSE52386.
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